Aller au contenu principal
  • Partenaires agréés
  • À propos d'ELGA
    • À propos d'ELGA
    • Carrières
    • Événements
  • Assistance
    • Aménagement du laboratoire
    • Enregistrer un produit
    • Register Your Product (USA & Canada Only)
  • Contact
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • Italia
  • Brasil
  • 日本
  • 中国
Accueil ELGA LabWater
  • Produits
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • Gamme complète des produits ELGA
  • Applications
    • Analyse microbiologique
    • Biochimie clinique
    • Chromatographie en phase gazeuse
    • Chromatographie en phase liquide
    • Cultures cellulaires
    • Exigences générales d'un laboratoire en matière d'eau
    • Génétique
    • Immunochimie
    • Spectrométrie de masse
    • Spectrophotométrie
    • Spectroscopie atomique
    • Électrochimie
  • Technologies
    • Charbon actif
    • Filtration
    • Osmose inverse
    • PureSure
    • Ultraviolet
    • Échange ionique
    • Électrodéionisation (EDI)
  • Impuretés dans l'eau
    • Composés inorganiques
    • Composés organiques
    • Gaz dissous
    • Micro-organismes et bactéries
    • Particules
  • Knowledge
    • Blog
    • Études de cas
    • Eau ultra-pure
    • Guides et livres blancs
  • Produits
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • Gamme complète des produits ELGA
      • PURELAB® Classic
  • Applications
    • Analyse microbiologique
    • Biochimie clinique
    • Chromatographie en phase gazeuse
    • Chromatographie en phase liquide
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • Cultures cellulaires
    • Exigences générales d'un laboratoire en matière d'eau
    • Génétique
    • Immunochimie
    • Spectrométrie de masse
    • Spectrophotométrie
    • Spectroscopie atomique
    • Électrochimie
  • Technologies
    • Charbon actif
    • Filtration
    • Osmose inverse
    • PureSure
    • Ultraviolet
    • Échange ionique
    • Électrodéionisation (EDI)
  • Impuretés dans l'eau
    • Composés inorganiques
    • Composés organiques
    • Gaz dissous
    • Micro-organismes et bactéries
    • Particules
  • Knowledge
    • Blog
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • Études de cas
      • Abbott Diagnostics opte pour les systèmes ELGA MEDICA en Asie du Sud
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA : la plus grande société de diagnostic médical au Brésil
      • ELGA aide les laboratoires d'immuno-sérologie à maximiser la disponibilité
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • Importance de l'eau ultra-pure de type 1+ pour la mise au point de médicaments génériques
      • MEDICA® Pro sélectionné pour les analyseurs Siemens ADVIA® à l'hôpital général de la ville
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex : un système de formation idéal pour la méthode de recherche actuelle
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • Découvrir les secrets de l'Antarctique à l'aide d'eau ultra-pure
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • Eau ultra-pure
    • Guides et livres blancs
      • Pureté de l'eau pour la HPLC
      • HPLC dans le secteur pharmaceutique
      • Réduire les risques cliniques
      • Durabilité
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • Italia
  • Brasil
  • 日本
  • 中国
  • Politique relative à la confidentialité
  • Conditions générales
  • Conformité juridique mondiale
  • Brevets
  • Impressum
  • Accueil
  • The Danger of Designer Benzodiazepines
Clinical & Pharma
Analytical Chemistry

The Danger of Designer Benzodiazepines

20 déc 2021
- by Dr Alison Halliday

Young depressed man sitting on floor

A case study of a fatal intoxication highlights the public health risk of ‘legal high’ substances that are commonly sold without effective restriction.

Designer benzodiazepines (DBZDs) are a class of novel psychoactive substances that have recently emerged onto the recreational drug market. They are commonly sold on the internet without restrictions at relatively low prices – or added to counterfeit products of approved benzodiazepines (BZDs), which are central nervous system (CNS) depressants used to treat anxiety and insomnia.

The European Monitoring Centre for Drugs and Drug Addiction is currently monitoring 30 DBZDs, 21 of which have entered the market since 2015. Up to now, data regarding the safety, toxicity, and potency of these substances is largely missing. Therefore, they represent a potential public health problem with a high risk for unintended intoxications and fatalities, especially when combined with other CNS depressants.

Flualprazolam is a novel DBZD that appeared on the market for the first time in 2017. It has since been seized as tablets, ‘blotters’ or in powder form in many European countries. But currently, there is very little known about the pharmacokinetics and pharmacodynamics of this novel psychoactive substance.

A Fatal Intoxication

A new report, published in Forensic Toxicology, describes a case of fatal multidrug intoxication involving flualprazolam.1 In February 2019, a 21–year–old male with a history of drug abuse, was found lying unresponsive on his bed. He was immediately brought to hospital and resuscitated but was declared dead approximately two hours later. 

Blood samples taken at the hospital and during a complete postmortem examination were available for analysis. General unknown screenings and analysis of drugs of abuse on postmortem samples were performed using immunoassay, gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) analyses. The scientists used deionised water prepared from an ELGA Medica® Pro deioniser, minimising the risk of adding contaminants that might affect the results of these sensitive analytical techniques.

The forensics team detected flualoprazolam in heart serum (25.4 ng/mL) and peripheral blood (21.9 ng/mL) as well as in urine, stomach contents, brain, liver and kidney. The cause of death was deemed as CNS and respiratory depression with the agonal aspiration of stomach contents. Given the concentrations of the co–consumed CNS depressants, the contribution of flualoprazolam to the death was considered likely (with a toxicological significance score of 3).

A Public Health Warning

These results support the hypothesis that highly potent DBZDs, like flualprazolam, carry an elevated risk for unintended toxicity, especially in combination with other CNS depressants that act to slow down brain activity. 

A comprehensive evaluation of fatalities remains mandatory, especially when there is a lack of pharmacological and toxicological data on intoxicating compounds. Given the potential for fatal intoxications, particularly when combined with other CNS depressants, their easy availability at relatively low prices and the elevated risk of unintended overdoses, DBZDs deserve increased attention from a public health perspective.

Why Choose ELGA LabWater?

ELGA LabWater has been a trusted name in pure and ultrapure water since 1937. We believe in giving you choice in how you use our water purification solutions, supported by excellent service and support.

 

Reference:

  1. Giorgetti, A. et al. A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues. Forensic Toxicol (2021) https://doi.org/10.1007/s11419-021-00591-w


Dr Alison Halliday

After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

risk whitepaper

When lives are at stake, there is no margin for error. Your clinical analyser must receive a constant and reliable supply of CLRW. 

Find out how to protect your test results

                   Click Here

 

  • Enquiry
  • Obtenir un devis
  • Réservez une démo
  • Trouver un partenaire approuvé

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Obtenir un devis

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Réservez une démo

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14
3BY Royaume-Uni
T : +44 (0) 203 567 7300 - Fax
 : +44 (0) 203 567 7205

Siège social ELGA LabWater

Lane End Business Park
Lane End, High Wycombe
HP14
3BY Royaume-Uni
T : +44 (0) 203 567 7300 - Fax
 : +44 (0) 203 567 7205

Études de cas

  • Diagnostics Abbott
  • Diagnostics médicaux DASA
  • Institut médical NeoDIN
  • Fondation North Staffordshire NHS Trust
  • Lycée professionnel d'Olsberg

Ressources

  • En savoir plus sur l'eau ultra-pure
  • Guides et livres blancs
  • Technologies de purification
  • Applications
  • Impuretés dans l'eau

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Langue
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Autres sites Veolia
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

© VWS (UK) Ltd. exerçant sous le nom ELGA LabWater.2023-Tous les droits sont réservés.
ELGA est la marque mondiale d'eau de laboratoire de Veolia.

  • Politique relative à la confidentialité
  • Conditions générales
  • Conformité juridique mondiale
  • Brevets
  • Impressum
Elga Veolia
TOP

© 2017 ELGA Veolia